New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2014
07:19 EDTALPMY, MDVNMedivation, Astellas Pharma submit sNDA for XTANDI
Astellas Pharma (ALPMY) and Medivation (MDVN) announced the submission of a supplemental New Drug Application, or sNDA, to the FDA seeking approval of XTANDI capsules for the treatment of men with metastatic castration-resistant prostate cancer, or mCRPC, who have not received chemotherapy. XTANDI is currently approved for the treatment of patients with mCRPC who have previously received docetaxel chemotherapy. The sNDA application is based on the results from the Phase 3 PREVAIL trial evaluating XTANDI as compared to placebo in more than 1,700 chemotherapy-na´ve mCRPC patients. The marketing authorization application is expected to be submitted to the European Medicines Agency later this year.
News For MDVN;ALPMY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 23, 2015
08:03 EDTMDVNMedivation lowered expectations skews risk/reward to upside, says UBS
UBS noted Medivation shares have been weak since ASCO but believes the risk reward has been skewed to the upside. The firm said its thesis is different from consensus as they believe the company's pipeline advancement this year could drive multiple expansion if Xtandi sales can at least remain flat. UBS reiterated its Buy rating and $142 price target on Medivation shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use